[1］吴一龙.局限晚期非小细胞肺癌[J］.肺癌杂志，2002.2～3（13～14）：21. [2］张季平.临床内科学[M］.天津：天津科学技术出版社，1999. [3］Ferrigno D，Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer：do new agents make adifference[J］.Lung Cancer，29(2000)：91. [4］翁开敏，贺全山.紫杉醇研究概况[J］.海峡药学，2002，14(2)：5. [5］马骁驰，吴立军，贾景明.紫杉醇类化合物研究概况与展望[J］.沈阳药科大学学报，2002，19（2）：147. [6］张湘茹，孙燕.紫杉醇治疗非小细胞肺癌[J］.中国新药杂志，1996，5（4）：245. [7］David S，Ettinger.Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer[J］.The Oncologist，2002，7：226. [8］Sandler AB，Nemunaitis J，Denham C，et al.Phase Ⅲ trial of gemcitabine plus cisplatin versus cisplatin along in patients with locally advanced or metastatic non-small cell lung cancer[J］.J Clin Oncol，2000，18：122. [9］Bonomi P，Kim K，Fairclough D，et al.Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etopside with cisplatin：results of an Eastern Cooperative Oncology Group trial[J］.J Clin Oncol，2000，18：623. [10］van Meerbeeck JP，Smit E，Lianes P，et al.A EORTC randomized phase Ⅲ trial of three chemotherapy regimen advanced non-small cell lung cancer (NSCLC)[J］.Proc Am Soc Clin Oncol，2001，20：308a. [11］潘起超.治疗非小细胞肺癌新药的进展[J］.癌症，1999，18(Suppl)：137. [12］张湘茹，孙燕，孔维红，等.去甲长春花碱加顺铂治疗晚期非小细胞肺癌42例[J］.中华肿瘤杂志，1998，20(1)：60. [13］韩福才，杨卫华，朱海波，等.NP方案治疗NSCLS的临床研究肿瘤，2000，20(6)：462. [14］Wozniak AJ，Crowley JJ，Balcerzak SP，et al.Randomized trial compareing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer：a Southwest Oncology Group Study[J］.J Clin Oncol，1998，16：2459. [15］Le Chevalier T，Brisgand D，Douillard JY，et al.Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine along in advanced non-small cell lung cancer：results of a European multicenter trial including 612 patients[J］.J Clin Oncol，1994，12：360. [16］Gatzemeier U. Indications for chemotherapy in stage Ⅳ non-small cell lung cancer[J］.Lung Cancer，2001，33(Suppl 1)：S109. [17］罗扬，张湘茹.吉西他宾治疗晚期非小细胞肺癌的现状[J］.中国癌症杂志，2001，11（1）：74. [18］Anderson H，Hopwood P，Stephens RJ，et al.Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome[J］.Br J Cancer，2000，83(4)：447. [19］Manegold C，Bergam B，Chemaissani A，et al.Single-agent gemcitabine versus cisplatin-etoposide：early results of a randomized phase-Ⅱ study in locally advanced or metastatic non-small-cell lung cancer[J］.Ann Oncol，1997，8：525. [20］Cardenal F，López-Cabrerizo MP，Antón A，et al.Randomized phase-Ⅲ study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer[J］.J Clin Oncol，1999，17：12. [21］Comella P，Frasci G，Panza N，et al.Cisplatin，gemcitabine，and vinorelbine combination therapy in advanced non-small-cell lung cancer：a phase-Ⅱ randomized study of the southern italy cooperative Oncology Group[J］.J Clin Oncol，1999，17：1526. [22］Crino L，Mosconi AM，Scagliotti GV，et al.Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer：a phase Ⅱ trial[J］.Semin Oncol，1998，25(Suppl 9)：23. [23］Manegold C，Zatloukal P，Krejcy K，et al.Gemcitabine in non-small cell lung cancer(NSCLC)[J］.Invest New Drugs，2000，18(1)：29. [24］Alexopoulos K，Kouroussis C，Androulakis N，et al.Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previpusly treated with platinum-based chemotherapy：a multicenter phase Ⅱtrial[J］.Cancer Chemother Pharmacol，1999，43(3)：257. [25］Nakanishi Y，Takayama K，Takano K，et al.Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer[J］.Am J Clin Oncol，1999，22(4)：399. [26］Herbst RS，Kies MS.ZD1839(IressaTM)in non-small cell lung cancer[J］.The Oncologist，2002，7(Suppl 4)：9.